U.S. patent application number 17/464256 was filed with the patent office on 2021-12-23 for surface disinfectant with residual biocidal property.
The applicant listed for this patent is MICROBAN PRODUCTS COMPANY, W.M. Barr & Company, Inc.. Invention is credited to Brian Patrick AYLWARD, Samuel James HANNA, Charles L. HAWES, Kevin Andrew KAVCHOK, Tian LAN, Dennis Earl SHIREMAN, Gina Parise SLOAN, Karen Terry WELCH.
Application Number | 20210392878 17/464256 |
Document ID | / |
Family ID | 1000005822473 |
Filed Date | 2021-12-23 |
United States Patent
Application |
20210392878 |
Kind Code |
A1 |
LAN; Tian ; et al. |
December 23, 2021 |
SURFACE DISINFECTANT WITH RESIDUAL BIOCIDAL PROPERTY
Abstract
A biofilm sealant is provided imparting a residual biocidal
property. The biofilm sealant is used to treat a surface to impart
a film having a capacity to quickly kill bacteria and other germs
for at least 24 hours after deposit of the film on a treated
surface. The disinfectant formulation biofilm sealant comprises a
polymer binder, wherein the polymer binder is an oxazoline
homopolymer or an extended or a modified polymer based on an
oxazoline homopolymer, and a biocidal compound.
Inventors: |
LAN; Tian; (Huntersville,
NC) ; HANNA; Samuel James; (Charlotte, NC) ;
SLOAN; Gina Parise; (Statesville, NC) ; AYLWARD;
Brian Patrick; (Concord, NC) ; WELCH; Karen
Terry; (Kannapolis, NC) ; SHIREMAN; Dennis Earl;
(Marion, AR) ; KAVCHOK; Kevin Andrew; (Charlotte,
NC) ; HAWES; Charles L.; (Cordova, TN) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
MICROBAN PRODUCTS COMPANY
W.M. Barr & Company, Inc. |
Huntersville
Memphis |
NC
TN |
US
US |
|
|
Family ID: |
1000005822473 |
Appl. No.: |
17/464256 |
Filed: |
September 1, 2021 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
16921365 |
Jul 6, 2020 |
11134674 |
|
|
17464256 |
|
|
|
|
15162094 |
May 23, 2016 |
10842147 |
|
|
16921365 |
|
|
|
|
14949046 |
Nov 23, 2015 |
10834922 |
|
|
15162094 |
|
|
|
|
62127075 |
Mar 2, 2015 |
|
|
|
62166403 |
May 26, 2015 |
|
|
|
62084917 |
Nov 26, 2014 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A01N 31/02 20130101;
A01N 33/12 20130101; A01N 59/02 20130101; A01N 25/10 20130101; A01N
59/00 20130101 |
International
Class: |
A01N 25/10 20060101
A01N025/10 |
Claims
1. A biocidal composition comprising: a polyoxazoline present in a
range of 0.1% to 4% based on the weight of the disinfectant
formulation, the polyoxazoline having a structure of ##STR00009##
wherein: R.sub.1 is methyl; R.sub.2 is hydroxyl; R.sub.3 is ethyl;
and n=10 to 1,000,000, and a quaternary ammonium compound or a
mixture of quaternary ammonium compounds present in a range of 0.1%
to 4% based on the weight of the disinfectant formulation, the
quaternary ammonium compound (QAC) having the molecular structure
of: ##STR00010## wherein R.sub.1 is methyl; R.sub.2 is alkyl C8-10;
methyl-benzyl; or ethyl-benzyl; R.sub.3 is methyl; R.sub.4 is alkyl
C8-18; and X.sup.- is chloride, or carbonate/bicarbonate; wherein
the biocidal composition is a biofilm sealant.
2. The biocidal composition according to claim 1, wherein the
polyoxazoline is prepared with a monomer of ethyloxazoline.
3. The biocidal composition according to claim 2, wherein
ethyloxazoline is copolymerized with a heterocyclic monomer.
4. The biocidal composition according to claim 1, wherein the
disinfectant formulation is in a form of a liquid.
5. The biocidal composition according to claim 1, wherein the
quaternary ammonium compound is present in a composition
comprising: N-alkyl dimethyl benzyl ammonium chloride, N-octyl
decyl dimethyl ammonium chloride, di-n-decyl dimethyl ammonium
chloride, and di-n-octyl dimethyl ammonium chloride.
6. The biocidal composition according to claim 5, wherein the
biocidal composition comprises: 40 weight % of N-alkyl dimethyl
benzyl ammonium chloride, 30 weight % of N-octyl decyl dimethyl
ammonium chloride, 15 weight % of di-n-decyl dimethyl ammonium
chloride, and 15 weight % of di-n-octyl dimethyl ammonium chloride,
wherein the percentage is a weight percentage of individual
quaternary ammonium compounds based on the total weight of the
quaternary ammonium compounds within the composition.
7. The biocidal composition according to claim 1, further
comprising a carrier comprised of a solvent or a mixture of
solvents.
8. The biocidal composition according to claim 7, wherein the
solvent or mixture of solvents comprise water, a low molecular
weight alcohol, alkylene glycol ether, a terpene or terpene
derivative, and a combination thereof.
9. The biocidal composition according to claim 8, wherein the
alcohol is present in an amount of at least 10%.
10. The biocidal composition according to claim 1, further
comprising a surfactant or a wetting agent.
11. The biocidal composition according to claim 10, wherein the
surfactant is present in a range of 0.01% to 2%.
12. A biocidal composition comprising: a polyoxazoline present in a
range of 0.1% to 4% based on the weight of the disinfectant
formulation, the polyoxazoline having a structure of ##STR00011##
wherein: R.sub.1 is methyl; R.sub.2 is hydroxyl; R.sub.3 is ethyl;
and n=10 to 1,000,000, a quaternary ammonium compound or a mixture
of quaternary ammonium compounds present in a range of 0.1% to 4%
based on the weight of the disinfectant formulation, and wherein
the composition is a biofilm sealant having a residual biocidal
property and the quaternary ammonium compound (QAC) has a molecular
structure of: ##STR00012## wherein R.sub.1 is methyl; R.sub.2 is
alkyl C8-10; methyl-benzyl; or ethyl-benzyl; R.sub.3 is methyl;
R.sub.4 is alkyl C8-18; and X.sup.- is chloride, or
carbonate/bicarbonate.
13. The biocidal composition according to claim 12, wherein the
polyoxazoline is prepared with a monomer of ethyloxazoline.
14. The biocidal composition according to claim 13, wherein
ethyloxazoline is copolymerized with a heterocyclic monomer.
15. The biocidal composition according to claim 12, wherein the
disinfectant formulation is in a form of a liquid.
16. The biocidal composition according to claim 12, wherein the
quaternary ammonium compound is present in a composition
comprising: N-alkyl dimethyl benzyl ammonium chloride, N-octyl
decyl dimethyl ammonium chloride, di-n-decyl dimethyl ammonium
chloride, and di-n-octyl dimethyl ammonium chloride.
17. The biocidal composition according to claim 16, wherein the
biocidal composition comprises: 40 weight % of N-alkyl dimethyl
benzyl ammonium chloride, 30 weight % of N-octyl decyl dimethyl
ammonium chloride, 15 weight % of di-n-decyl dimethyl ammonium
chloride, and 15 weight % of di-n-octyl dimethyl ammonium chloride,
wherein the percentage is a weight percentage of individual
quaternary ammonium compounds based on the total weight of the
quaternary ammonium compounds within the composition.
18. The biocidal composition according to claim 12, further
comprising a carrier comprised of a solvent or a mixture of
solvents.
19. The biocidal composition according to claim 18, wherein the
solvent or mixture of solvents comprise water, a low molecular
weight alcohol, alkylene glycol ether, a terpene or terpene
derivative, and a combination thereof.
20. The biocidal composition according to claim 19, wherein the
alcohol is present in an amount of at least 10%.
21. The biocidal composition according to claim 12, further
comprising a surfactant or a wetting agent.
22. The biocidal composition according to claim 21, wherein the
surfactant is present in a range of 0.01% to 2%.
23. A method of using the biocidal composition according to claim
1, the method comprising: sealing a surface with the biocidal
composition.
24. A method of using the biocidal composition according to claim
12, the method comprising: sealing a surface with the biocidal
composition.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation application of U.S.
patent application Ser. No. 16/921,365, filed Jul. 6, 2020, which
is a continuation application of U.S. Ser. No. 15/162,094, filed
May 23, 2016, which application is continuation-in-part patent
application of Ser. No. 14/949,046, filed on Nov. 23, 2015 which
claims priority from U.S. provisional patent application Ser. No.
62/084,917, filed on Nov. 26, 2014, and from U.S. provisional
patent application Ser. No. 62/127,075, filed on Mar. 2, 2015, and
from U.S. provisional patent application Ser. No. 62/166,403, filed
on May 26, 2015, in the United States Patent and Trademark Office.
The disclosures of which are incorporated herein by reference in
their entireties.
FIELD OF THE INVENTION
[0002] The present invention relates to the field of disinfectant
formulations, and more specifically, to a disinfectant formulation
imparting a residual biocidal property.
BACKGROUND OF THE INVENTION
[0003] Microbes exist everywhere in the modern world. While some
are beneficial to humans and the environment, others may have
significant negative consequences for contaminated articles as well
as the persons, animals and ecological members coming in contact
with them. There are a number of industries and environments where
such microbes are especially prevalent.
[0004] Healthcare
[0005] A hospital-acquired infection (HAI; alternatively a
"nosocomial infection") is an infection whose development is
favored by a hospital or healthcare environment. Such maladies
typically are fungal or bacterial infections and can afflict the
victim locally or systemically. Nosocomial infections can cause
severe pneumonia as well as infections of the urinary tract,
bloodstream, and other parts of the body.
[0006] Nosocomial infections have severe medical implications for
patients and care providers. In the United States, data suggest
that approximately 1.7 million instances of hospital-associated
infections occur each year, with nearly 100,000 deaths resulting
therefrom. European data and surveys indicate Gram-negative
bacterial infections alone account for 8,000-10,000 deaths each
year.
[0007] Several aggravating factors contribute to the high HAI rate.
Hospitals, urgent care centers, nursing homes, and similar
facilities focus their treatments on those with serious illnesses
and injuries. As a result, these facilities house abnormally highly
concentrated populations of patients with weakened immune
systems.
[0008] A trio of pathogens is commonly found in healthcare settings
and together account for approximately one-third of nosocomial
infections: coagulase-negative Staphylococci (15%), Candida species
(11%), and Escherichia coli (10%).
[0009] Worse, it is the more robust disease-causing pathogens that
are present in such environments. The six so-called "ESKAPE
pathogens"--Enterococcus faecium, Staphylococcus aureus, Klebsiella
pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and
Enterobacter species--possess antibiotic resistance and are
implicated in nearly half of all nosocomial infections. Their
resistance to one or more biocidal agents makes such infections
particularly dangerous.
[0010] In particular, the broad nutritional versatility of
Pseudomonas permits its survival in extreme environments, including
survival on surfaces not intensively cleaned and sterilized. This
pathogen's ubiquity in the hospital environment makes it a leading
cause of Gram-negative nosocomial infections. Particularly
vulnerable are immune-compromised patients (e.g. those afflicted
with cystic fibrosis, cancer, or burns).
[0011] The most common means of HAIs is through direct or indirect
contact transmission. Direct contact transmission involves a
patient contacting either a contaminated patient or worker. As care
providers move through the healthcare institution, they come into
contact with its many patients. These workers unwittingly act in a
manner analogous to bees in a garden, "pollinating" rooms and wards
as they care for residents.
[0012] Indirect contact transmission occurs when the patient
contacts a contaminated object or surface. The healthcare
environment presents an array of articles capable of passively
vectoring pathogens.
[0013] Nosocomial infections further deal a serious blow to the
volume, quality, and cost of healthcare provided by hospitals and
other institutions. In addition to the roughly 100,000 HAI-related
deaths occurring annually in the United States, an estimated two
million more victims are forced to endure the physical ravages and
emotional distress associated with these serious and avoidable
illnesses.
[0014] Institutions have reacted by creating policies to impose
more stringent cleanliness and disinfection requirements upon staff
and the patient environment. These programs typically include
frequent hand-washing and frequent disinfection of surfaces.
Despite implementation of programs to curb nosocomial infections,
infections still occur at unacceptably high rates.
[0015] Home Care and Household
[0016] Household environments also face microbes. A main
disadvantage associated with consumer disinfectants and sanitizers
is that, while they can be effective at initially killing microbes,
the surface is easily and quickly re-contaminated through contact,
airborne microbes, and un-killed residual microbes before
treatment. While some of the disinfectants would continue to offer
some control if simply left on the surface, this would result in a
greasy or tacky residue that would be easily negated by casual
contact with the surface. Thus, there is a desire for a home care
and household cleaner that kills microbes quickly on contact, then
acts as a residual disinfectant but yet does not have this
undesirable sticky or tacky effect. Such cleaners may be useful for
general purpose household cleaning, bathroom cleaning, and spray
protectants.
[0017] A difference between hospital and healthcare cleaners and
household products is the allowable VOC (volatile organic content).
The regulations for most non-aerosol household consumer
disinfectants are a maximum of 1% VOC.
[0018] Food Service
[0019] The food service industry also faces outbreaks in
contamination of pathogens in the workplace and spreading disease
out to consumers. Even though food manufacturers adopt vigorous
hygiene plans and comply with tight government hygiene regulations,
major outbreaks of microbes are still reported occasionally that
causes serious illness among consumers. Disinfectants with residual
activities should effectively alleviate the issue.
[0020] Biofilm
[0021] A biofilm is generally defined as a layer of microorganisms
adhering to the surface of a structure, which may be organic or
inorganic, that secrete a protective coating that is biological in
origin. Biofilms present a large problem for public health because
of increased resistance of biofilm-associated organisms to
antimicrobial agents and for the potential of biofilm borne
organisms to cause infections. Thus, there is a need for a solution
to disinfection with regard to biofilms. Current disinfectants do
not have the ability to kill biofilms or to seal or lock-in
biofilms on surfaces to prevent cross-contamination events and to
prevent out growth. There are limited solutions for surface biofilm
problems. For example, there is a building body of evidence that
surface biofilms pose a problem in the healthcare setting for the
above mentioned reasons. In addition, biofilms are a recognized
problem of possible contamination within the food industry. Other
industries face similar concerns. Thus, there is a need for a
solution targeted at potential biofilm problem areas that can be
used to eradicate biofilms.
[0022] In summary, there remains a need for a formulation able to
confer a residual biocidal activity to treated surfaces. It would
be further advantageous if the formulation were combined with a
surface disinfectant, to enable a single cleaning to both disinfect
and impart the residual biocidal effect.
[0023] It further would be advantageous for the residual biocidal
property to be durably associated with the treated surface, such
that it may continue to provide microbial reduction for an extended
period of time after application.
[0024] It further would be advantageous if there is a
formulation(s) effective across a wide range of industries and
applications.
SUMMARY OF THE INVENTION
[0025] The present invention relates to a disinfectant formulation
imparting a residual biocidal property. The disinfectant
formulation comprises a polymer binder, wherein the polymer binder
is an oxazoline homopolymer or an extended or a modified polymer
based on an oxazoline homopolymer, and a biocidal compound. The
disinfectant formulation further comprises a carrier.
[0026] In an aspect of the invention the oxazoline homopolymer has
a structure of:
##STR00001##
wherein R.sub.1 is a hydrogen, alkyl, alkenyl, alkoxy, alkylamino,
alkynyl, allyl, amino, anilino, aryl, benzyl, carboxyl,
carboxyalkyl, carboxyalkenyl, cyano, glycosyl, halo, hydroxyl,
oxazolinium mesylate, oxazolinium tosylate, oxazolinium triflate,
silyl oxazolinium, phenolic, polyalkoxy, quaternary ammonium,
thiol, or thioether group; R.sub.2 is a hydrogen, alkyl, alkenyl,
alkoxy, alkylamino, alkynyl, allyl, amino, anilino, aryl, benzyl,
carboxyl, carboxyalkyl, carboxyalkenyl, cyano, glycosyl, halo,
hydroxyl, oxazolinium mesylate, oxazolinium tosylate, oxazolinium
triflate, silyl oxazolinium, phenolic, polyalkoxy, quaternary
ammonium, thiol, or thioether group or a macrocyclic structure;
R.sub.3 is a hydrogen, alkyl, alkenyl, alkoxy, aryl, benzyl,
hydroxyalkyl, or perfluoroalkyl group; and n is in a range of 1 to
1,000,000.
[0027] In another aspect of the invention other features of the
disinfectant formulation(s) are provided.
[0028] In yet another aspect of the invention, an article having
the disinfectant formulation(s) of the present invention is
provided as well as methods of making, using and applying the
disinfectant formulation(s).
[0029] Further areas of applicability of the present invention will
become apparent from the detailed description provided hereinafter.
It should be understood that the detailed description and specific
examples, while indicating the preferred embodiments of the
invention, are intended for purposes of illustration only and are
not intended to limit the scope of the invention
DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0030] The following description of the embodiments of the present
invention is merely exemplary in nature and is in no way intended
to limit the invention, its application, or uses. The present
invention has broad potential application and utility, which is
contemplated to be adaptable across a wide range of industries. The
following description is provided herein solely by way of example
for purposes of providing an enabling disclosure of the invention,
but does not limit the scope or substance of the invention.
[0031] As used herein, the terms "microbe" or "microbial" should be
interpreted to refer to any of the microscopic organisms studied by
microbiologists or found in the use environment of a treated
article. Such organisms include, but are not limited to, bacteria
and fungi as well as other single-celled organisms such as mold,
mildew and algae. Viral particles and other infectious agents are
also included in the term microbe.
[0032] "Antimicrobial" further should be understood to encompass
both microbicidal and microbistatic properties. That is, the term
comprehends microbe killing, leading to a reduction in number of
microbes, as well as a retarding effect of microbial growth,
wherein numbers may remain more or less constant (but nonetheless
allowing for slight increase/decrease).
[0033] For ease of discussion, this description uses the term
antimicrobial to denote a broad spectrum activity (e.g. against
bacteria and fungi). When speaking of efficacy against a particular
microorganism or taxonomic rank, the more focused term will be used
(e.g. antifungal to denote efficacy against fungal growth in
particular).
[0034] Using the above example, it should be understood that
efficacy against fungi does not in any way preclude the possibility
that the same antimicrobial composition may demonstrate efficacy
against another class of microbes.
[0035] For example, discussion of the strong bacterial efficacy
demonstrated by a disclosed embodiment should not be read to
exclude that embodiment from also demonstrating antifungal
activity. This method of presentation should not be interpreted as
limiting the scope of the invention in any way.
[0036] Disinfectant Formulation
[0037] The present invention is directed to a disinfectant
formulation. In an aspect of the invention, the disinfectant
formulation is in a liquid form. The composition of the
disinfectant formulation comprises a biocidal compound and a
polymer binder. The composition may further comprise a solvent
(such as water or a low molecular weight alcohol), a surfactant, a
colorant, a fragrance, among other components.
[0038] A liquid composition is formulated having surface
disinfection and residual biocidal properties. The formulation can
be applied to a surface by spraying, rolling, fogging, wiping or
other means. The formulation acts as a surface disinfectant,
killing infectious microbes present on the surface.
[0039] Once dried, the liquid formulation leaves a residual
protective film on the surface. The residual film possesses a
biocidal property, enabling it to maintain protection of the
surface against microbial contamination for an extended time period
after its application.
[0040] In a preferred embodiment, the surface disinfectant
formulation imparts a film with the capacity to quickly kill
bacteria and other germs for at least 24 hours after deposit of the
film on the treated surface. In an aspect of the invention, quick
kill generally refers to a time period of about 30 seconds to about
5 minutes. The film will remain on the surface and is durable to
multiple touches and wearing of the surface.
[0041] In another embodiment of the present invention, the
disinfectant formulation is a liquid composition comprising a
polymer binder, a biocidal compound, a carrier such as a solvent,
and other optional components such as fragrances.
[0042] Biofilm Sealant
[0043] In an embodiment of the present invention, the disinfectant
formulation is a biofilm sealant. The biofilm sealant once applied
to a surface forms a polymer film. The polymer film is applied wet
and dries as a film layer to lock in and prevent subsequent
outgrowth of biofilm microorganisms. The biofilm sealant, although
preferably in the form of a liquid, may also take other forms such
as a gel, or other form. Once the biofilm sealant is in place, the
microbes of the biofilm have limited access to oxygen and exogenous
nutrients. The biofilm sealant has the potential to seal in
bacteria but also to provide extended release of antimicrobials
into the film to kill the microorganisms in the biofilm.
[0044] In an embodiment of the present invention, the biofilm
sealant comprises a polymer binder and a biocidal compound. The
biocidal compound may include, but is not limited to, any biocidal
compound set forth herein.
[0045] In an embodiment of the present invention, the biofilm
sealant comprises an oxazoline homopolymer as the polymer binder.
The oxazoline homopolymer may have any of the structures as set
forth herein.
[0046] In an embodiment of the present invention, the biofilm
sealant comprises a polymer binder, a biocidal compound, and an
enzyme(s). The enzyme is to assist in degrading the biofilm and
provide for enhanced antimicrobial penetration by the biocidal
agent and ultimately biofilm removal. Example enzymes include, but
are not limited to, proteinase, DNase, RNase, and carbohydrate
specific enzymes that can degrade the extracellular matrix
associated with the biofilm.
[0047] In an embodiment of the present invention, the biofilm
sealant comprises a polymer binder and an antibody as a biological
material for slow release into the film. The antibody functionality
will bind to the biofilm microbe to prevent
cross-contamination.
[0048] In an embodiment of the present invention, the biofilm
sealant comprises a polymer binder, and a bacteriophage or a
mixture of bacteriophages as a biological material for slow release
into the film. The bacteriophage act as a targeted antimicrobial
agent to kill biofilm associated organisms.
[0049] In an embodiment of the present invention, the biofilm
sealant comprises a polymer binder, and a mixture of
bacteriophages, antimicrobial agents, enzymes and antibodies as a
biological material for slow release into the film.
[0050] Polymer Binder
[0051] In an aspect of the invention, the polymer binder is an
oxazoline homopolymer. As another feature of the invention, the
oxazoline homopolymer has the following structure:
##STR00002##
[0052] wherein
[0053] R.sub.1 and R.sub.2 are end groups determined by the
polymerization techniques used to synthesize oxazoline homopolymer.
R.sub.1 and R.sub.2 are independently selected and include, but are
not limited to, hydrogen, alkyl, alkenyl, alkoxy, alkylamino,
alkynyl, allyl, amino, anilino, aryl, benzyl, carboxyl,
carboxyalkyl, carboxyalkenyl, cyano, glycosyl, halo, hydroxyl,
oxazolinium mesylate, oxazolinium tosylate, oxazolinium triflate,
silyl oxazolinium, phenolic, polyalkoxy, quaternary ammonium,
thiol, or thioether groups. Alternatively, R.sub.2 could include a
macrocyclic structure formed during synthesis as a consequence of
intramolecular attack.
[0054] For example, R.sub.1 is a methyl group and R.sub.2 is
oxazolinium tosylate if methyl tosylate is used as the initiator in
the cationic initiated polymerization of oxazoline.
[0055] R.sub.3 is an end group determined by the type of oxazoline
used in the preparation of the polymer binder of this invention.
R.sub.3 includes, but is not limited to, hydrogen, alkyl, alkenyl,
alkoxy, aryl, benzyl, hydroxyalkyl, or perfluoroalkyl. For example,
R.sub.3 is an ethyl group if ethyloxazoline is the monomer used to
prepare the polymer binder for the present invention.
[0056] n is the degree of oxazoline polymerization in the
homopolymer. n is in a range of 1 to 1,000,000. Preferably, n is in
a range of 500 to 250,000; most preferably, n is in a range of 2500
to 100,000.
[0057] Similar to oxazoline homopolymer, extended or modified
polymers with some variations based on the oxazoline homopolymer
are also suitable for the present invention. The techniques and
options for performing chemical or molecular structure variations
or modifications to oxazoline should be familiar to those skilled
in the art. A class of extended or modified polymers based on
oxazoline homopolymer can be represented with the following
molecular structure:
##STR00003##
[0058] wherein
[0059] R.sub.1 and R.sub.3 have the same definition as those given
in the above oxazoline homopolymer.
[0060] B is additional monomer repeating unit linked to oxazoline
in a coploymer. The types of arrangement of the repeating units
between B and oxazoline in the copolymer can include, but are not
limited to, block, alternating, periodic, or combinations thereof.
There is no limitation as to the types of B that can be used to
copolymerize with or modify the oxazoline of the present
invention.
[0061] n is the degree of polymerization for an oxazoline repeating
unit; n in the copolymer is in a range of 1 to 1,000,000 and the
degree of polymerization for B repeating unit in the copolymer m is
in a range of 0 to 500,000 at the same time. Preferably, n is in a
range of 500 to 250,000 and m is in a range of 20 to 10,000; and
most preferably, n is in a range of 2500 to 100,000 and m is in a
range of 50 to 5,000. In addition to linking B to ethyloxazoline
through copolymerization, B could also be linked to oxazoline as an
end group in a cationic polymerization by using B as a cationic
initiator if B itself is already a quaternary ammonium
compound.
[0062] Not intended to be all inclusive, B can be, for example,
ethyleneimine with the following molecular structure:
##STR00004##
[0063] wherein
[0064] R.sub.1 and R.sub.2 end groups have the same definition as
those outlined for oxazoline homopolymer.
[0065] R.sub.3 includes, but is not limited to, hydrogen, alkyl,
alkenyl, alkoxy, aryl, benzyl, hydroxyalkyl, or perfluoroalkyl.
[0066] R.sub.4 includes, but is not limited to, hydrogen, alkyl,
alkenyl, alkoxy, aryl, benzyl, hydroxyalkyl, or perfluoroalkyl.
[0067] m is in a range of 0 to 500,000; preferably, in a range of
20 to 10,000; and
[0068] most preferably, in a range of 50 to 5,000.
[0069] n is in a range of 1 to 1,000,000; preferably, 500 to
250,000; most preferably, in a range of 2500 to 100,000.
[0070] The synthesis of oxazoline and ethyleneimine copolymer can
be phased into two steps, for example. In a first step, a cationic
ring opening polymerization technique can be used to make
polyoxazoline homopolymer. In a second step, the polyoxazoline made
in the first step can be hydrolyzed to convert part of
polyoxazoline repeating units into polyethyleneimine.
Alternatively, oxazoline-ethylenimine copolymer can be made with
the appropriate respective monomers, an oxazoline and an aziridine.
The result would be a cationic polymer having the above
structure.
[0071] The degree of polymerization for oxazoline repeating unit n
in the copolymer is in a range of 1 to 1,000,000 and the degree of
polymerization for ethyleneimine repeating unit in the copolymer m
is in a range of 0 to 500,000 at the same time. Preferably, n is in
a range of 500 to 250,000 and m is in a range of 20 to 10,000, and
most preferably n is in a range of 2500 to 100,000 and m is in a
range of 50 to 5,000.
[0072] Alternatively, the nitrogen in the ethyleneimine repeating
unit could be further quarternized to generate the following
cationic copolymer:
##STR00005##
Any quaternization technique that is familiar to those skilled in
the art could be used to quaternize the polymer of this example.
R.sub.1, R.sub.2, R.sub.3 and R.sub.4 have the same meaning as
those designated in the above oxazoline-ethyleneimine copolymer.
R.sub.5 includes, but is not limited to, a hydrogen, methyl, ethyl,
propyl, or other types of alkyl group. The corresponding anion
X.sup.- is a halogen, sulfonate, sulfate, phosphonate, phosphate,
carbonate/bicarbonate, hydroxy, or carboxylate.
[0073] The ranges for n and m are also the same as those described
in oxazoline-ethyleneimine copolymer.
[0074] Another example of B that can be used for the present
invention is polydiallyldimethylammonium chloride.
Polyethyloxazoline modified with polydiallyldimethylammonium
chloride has the following structure:
##STR00006##
[0075] wherein
[0076] R.sub.1 and R.sub.4 have the same meaning as described in
previous example for quarternized oxazoline-ethyleneimine
copolymer.
[0077] R.sub.2 and R.sub.3, independently, include, but are not
limited to, short chain alkyl groups such as C1 to C6. The
corresponding anion X.sup.- is a halogen, sulfonate, sulfate,
phosphonate, phosphate, carbonate/bicarbonate, hydroxy, or
carboxylate.
[0078] n and m are defined and numbered the same as in previous
examples.
[0079] B could be other olefins including, but not limited to,
diallyldimethylammonium chloride, styrene, methoxy styrene, and
methoxyethene. Ethyloxazoline can also be copolymerized with
heterocyclic monomers such as oxirane, thietane, 1,3-dioxepane,
oxetan-2-one, and tetrahydrofuran to enhance the performance of the
polymer for the present invention. The binder used in this
invention could also employ pendant oxazoline groups on a polymer
backbone, such as an acrylic or styrene based polymer, or a
copolymer containing acrylic or styrene.
[0080] Examples of commercially available polyethyloxazolines
include, but are not limited to, Aquazol 500 from Polymer Chemistry
Innovations, Inc.
[0081] The amount of polymer binder that can be used in the liquid
formulation can vary somewhat depending upon desired length of
residual activity of the composition and the nature of all the
other components in the composition. Preferably, the amount of
polymer binder in the liquid formulation is in a range of 0.1% to
20% based on the weight of liquid formulation. In a liquid
formulation for healthcare applications, the amount of polymer
binder in the liquid formulation is more preferably in a range of
0.5% to 10%, and most preferably in a range of 0.8% to 5%. In
liquid formulations for all-purpose and bathroom cleaners, the
amount of polymer binder in the liquid formulation is more
preferably in a range of 0.1% to 10%, and most preferably in a
range of 0.1% to 5%.
[0082] The polymer binder preferably is water-soluble and can be
readily removed from surface if any buildup is noticed. Present in
small amounts, it nonetheless can provide a durable bond between
biocidal compound and the treated surface to facilitate residual
efficacy.
[0083] Biocidal Compound
[0084] The biocidal compound may be a quaternary ammonium compound
(QAC) with the following molecular structure:
##STR00007##
[0085] wherein
[0086] R.sub.1, R.sub.2, R.sub.3, and R.sub.4 are independently
selected and include, but are not limited to, alkyl, alkoxy, or
aryl, either with or without heteroatoms, or saturated or
non-saturated. Some or all of the functional groups may be the
same.
[0087] The corresponding anion X.sup.- includes, but is not limited
to, a halogen, sulfonate, sulfate, phosphonate, phosphate,
carbonate/bicarbonate, hydroxy, or carboxylate.
[0088] QACs include, but are not limited to, n-alkyl dimethyl
benzyl ammonium chloride, di-n-octyl dimethyl ammonium chloride,
dodecyl dimethyl ammonium chloride, n-alkyl dimethyl benzyl
ammonium saccharinate, and 3-(trimethoxysilyl)
propyldimethyloctadecyl ammonium chloride.
[0089] Combinations of monomeric QACs are preferred to be used for
the invention. A specific example of QAC combination is N-alkyl
dimethyl benzyl ammonium chloride (40%); N-octyl decyl dimethyl
ammonium chloride (30%); di-n-decyl dimethyl ammonium chloride
(15%); and di-n-dioctyl dimethyl ammonium chloride (15%). The
percentage is the weight percentage of individual QAC based on the
total weight of blended QACs composition.
[0090] Polymeric version of the QACs with the following structures
can also be used for the invention.
##STR00008##
[0091] wherein
[0092] R.sub.1, R.sub.2, R.sub.5, and R.sub.6, independently,
include, but are not limited to, hydrogen, methyl, ethyl, propyl or
other longer carbon alkyl groups.
[0093] R.sub.3 and R.sub.4 are independently selected and include,
but are not limited to, methylene, ethylene, propylene or other
longer alkylene linking groups.
[0094] n is the degree of polymerization; n is an integer in a
range of from 2 to 10,000.
[0095] Examples of cationic polymers with the above structure,
include but are not limited to, polyamines derived from
dimethylamine and epichlorohydrin such as Superfloc C-572
commercially available from Kemira Chemicals.
[0096] Still another polymeric QAC suitable for the invention is
poly diallyldimethylammonium chloride or polyDADMAC.
[0097] Yet another class of QACs useful for the present invention
are those chemical compounds with biguanide moiety in the molecule.
Examples of this class of cationic antimicrobials include, but are
not limited to, PHMB and chlorhexidine.
[0098] Examples of commercially available quaternary ammonium
compounds include, but are not limited to, Bardac 205M and 208M
from Lonza, and BTC885 from Stepan Company.
[0099] The biocidal compound may be a weak acid, which has been
shown to be particularly effective in bathroom cleaners. In these
type of products, citric, sulfamic (also known as amidosulfonic
acid, amidosulfuric acid, aminosulfonic acid, and sulfamidic acid),
glycolic, lactic, lauric and capric acids are useful as both an
effective biocide and a cleaning agent for soap scum and hard wart
deposits.
[0100] Other compounds which may be useful are silane quaternary
salts such as 3(trihydroxysilyl)propyldimethyloctadecyl ammonium
chloride. These may have the added benefit of reacting to the
surface being treated for an enhancement of the residual
properties.
[0101] Further biocidal compounds suitable for use in the present
liquid formulation span a broad range of antimicrobials, biocides,
sanitizers, and disinfectants. A water soluble or dispersible
biocidal compound is preferred, although biocides soluble in
alcohol may be alternatively employed.
[0102] A non-exhaustive list of biocidal compounds suitable for use
in the present formulation include triclosan, zinc pyrithione,
metal salts and oxides, phenols, botanicals, halogens, peroxides,
heterocyclic antimicrobials, aldehydes, and alcohols.
[0103] The concentration of biocidal compound in the formulation
can be in a range of 0.05% to 20% based on the weight of the liquid
composition. For a liquid formulation for a healthcare application,
preferably in a range of 0.1% to 20%, and more preferably in a
range of 0.5% to 3%. For a liquid formulation for all-purpose and
bathroom cleaners, preferably in a range of 0.05% to 10%. For a
formulation for a protectant, preferably in a range of 0.05% to
2%.
[0104] Carrier
[0105] The carrier or media for the liquid formulation of this
invention can be any solvent that is volatile and allow easy
evaporation at ambient condition. Examples of liquid carriers
include, but are not limited to, water and low molecular weight
alcohols such as C1 to C8 alkanols. Specific examples include, but
are not limited to, ethanol, isopropyl alcohol, butanol, pentanol,
and combinations thereof.
[0106] Another class of solvents for use in the invention includes
alkylene glycol ether. Examples include, but are not limited to,
ethylene glycol monopropyl ether, ethylene glycol monobutyl ether,
ethylene glycol monohexyl ether, ethylene clycol monohexyl ether,
diethylene glycol monomethyl ether, diethylene glycol monoethyl
ether, diethylene glycol monobutyl ether, diethylene glycol
monohexyl ether, triethylene glycol monomethyl ether, triethylene
glycol monoethyl ether, triethylene glycol monobutyl ether,
propylene glycol methyl ether, propylene glycol methyl ether
acetate, propylene glycol n-butyl ether, dipropylene glycol n-butyl
ether, dipropylene glycol methyl ether, dipropylene glycol methyl
ether acetate, propylene glycol n-propyl ether, dipropylene glycol
n-propyl ether, and tripropylene glycol methyl ether.
[0107] Another class of solvents for use in the invention is based
on terpenes and their derivatives such as terpene alcohols, terpene
esters, terpene ethers, or terpene aldehydes. Examples of solvents,
include but are not limited to, pine oil, lemon oil, limonene,
pinene, cymene, myrcene, fenchone, borneol, nopol, cineole, ionone
and the like.
[0108] A preferred carrier in a liquid formulation for a home care
cleaning application is water.
[0109] If the method of the application of the liquid formulation
of the present invention is pressurized aerosol, a propellant may
be needed in the composition. A variety of propellants or mixtures
can be used for the present invention and should be familiar to
those skilled in the art. C1 to C10 hydrocarbons or halogenated
hydrocarbons are typical propellants in aerosol compositions known
to the industry. Examples of such propellants include, but are not
limited to, pentane, butane, propane, and methane. Other types of
propellants that can be used for the present invention also include
compressed air, nitrogen, or carbon dioxide. Alternatively, a bag
on valve package may be used to aerosol the product without
directly add a propellant to the composition.
[0110] Either a single solvent or a mixture of the above solvents
can be used for the present invention. The types of solvents used
for the present invention may depend upon the intended uses of the
residual disinfectant composition. For example, if the composition
of the present invent is intended for home care use, cleaning the
contaminated surfaces free of all types of dirt or soil may be of
primary interest. Liquid carrier or media that assist and enhance
the removal of soil may be formulation of the invention. For
example, the residual disinfectant formulation or composition of
the present invention may desire to include alkyl or multi-alkyl
glycol ethers for better cleaning performance in the home care
version of the formulation of the present invention. On the other
hand, if the primary goal of the residual disinfectant composition
is to be used at a health care facility where the major concern is
hospital acquired infection, then quick drying of the liquid
composition of the present invention may be more desirable than
cleaning dirt or soil out of the surfaces. Low molecular weight
alcohols should be considered to help the liquid formulation of the
present invent dry fast after the application. Also, a low
molecular weight alcohol in the liquid formulation will strengthen
the sanitizing activity of the liquid composition.
[0111] For health care use of the residual disinfectant, a mixture
of water and low molecular weight alcohol is preferred. The amount
of alcohol present in the liquid formulation is preferred to be at
such a level that the liquid formulation is capable of forming a
zerotropic mixture between the alcohol and water. A minimum amount
of alcohol, if present, in the liquid composition is 10%.
Preferably, for health care use of the residual disinfectant, the
alcohol concentration is 30%, and most preferably the alcohol
concentration is at least 50% based on the weight of liquid
formulation for the health care use of the composition of the
invention.
[0112] Surfactant
[0113] A surfactant or wetting agent may be employed. The
surfactant assists the liquid formulation to spread and evenly coat
the surface being treated. The surfactant additionally contributes
to the formation of a zeotropic mixture between alcohol and water,
thus facilitating a rapid and uniform drying of the liquid
formulation once being applied onto surface. A surfactant also
plays an important role in the residual disinfectant liquid
formulation of the present invention for home care use if the soil
cleaning performance is the key feature the product is designed to
possess.
[0114] Surfactants appropriate for the present liquid formulation
include, but are not limited to, those that are nonionic, anionic,
or amphoteric in nature. Examples of commercially available wetting
agents include, but are not limited to, Ecosurf SA-4 or Tergitol
TMN-3 from Dow Chemical, and Q2-5211 from Dow Corning.
[0115] An amine oxide surfactant is preferred especially when the
QAC is used as the biocidal compound in the formulation.
[0116] In the category of nonionic surfactants, ethoxylated
alcohols with different amounts of ethylene oxides or HLB values
can be used. Examples of ethoxylated alcohols include, but are not
limited to, Triton X-100 (Dow Chemical, Midland Mich.), Ecosurf EH
nonionic surfactant series from Dow Chemical, Tergitol nonionic
surfactant series from Dow Chemical, the Surfonic surfactant series
from Huntsman Corp., the Neodol surfactant series from Shell, the
Ethox surfactant series from Ethox Chemicals and the Tomadol
surfactant series from Air Products and Chemicals, Inc.
[0117] Another class of nonionic surfactants include
alkylpolyglucosides. Examples include the Glucopon Series from BASF
and the Ecoteric series from Huntsman.
[0118] An alternative class of surfactants that is preferred for
the liquid formulation are silane-based surfactants. Examples
include but, are not limited to, silicone polyethers
organofunctional or reactive silane wetting agents, and
fluorochemical based wetting agents.
[0119] The content of the surfactant in the liquid formulation is
in a range of 0% to 10%, preferably in a range of 0.01% to 5%.
[0120] Depending on the targeted uses, a liquid formulation of the
present invention for home care use may need appropriate pH
condition. For example, if the liquid product is used in the
kitchen area, a high pH product may be desired in order to
effectively remove grease soils commonly found in the area. If the
product is used in bathroom area, soap scum and hard water deposits
may be the primary concern. In such case, a low pH product may be
more appropriate for such a purpose. There is no limitation on the
types of pH adjusting agents that can be added into the liquid
composition of the present invention. Example of pH adjusting
agents that can be used include, but are not limited to,
triethanolamine, diethanolamine, monoethanolamine, sodium
hydroxide, sodium carbonate, potassium hydroxide, potassium
carbonate, calcium carbonate, citric acid, acetic acid,
hydrochloric acid, sulfamic acid, sulfuric acid and the like.
[0121] Other than components mentioned above, additional functional
components may be included in the liquid composition of the present
invention. Additional components include, but are not limited to,
chelants, compatibilizers, coupling agents, corrosion inhibitors,
rheology modifiers, fragrances, colorants, preservatives, UV
stabilizers, optical brighteners, and active ingredient
indicators.
[0122] In an embodiment of the present invention, the liquid
solution comprises a polymer binder, a quaternary ammonium
compound, a silicone-based surfactant, and ethanol. The liquid
formulation can be made or mixed by any conventional method known
to one of ordinary skill in the art. There are no preferred
addition procedures for the formulation of the present invention
provided that the formulation is ultimately homogeneous, compatible
and stable. For example, if the polymer binder is a solid, it may
be preferable to first dissolve or disperse the polymer in a
carrier such as water or alcohol to make a stock polymer binder
liquid dispersion. The stock polymer binder liquid dispersion may
be readily added into the formulation of the present invention
during the mixing procedure.
[0123] Application of Liquid Formulation
[0124] The liquid formulation may be applied by a variety of means.
If sprayed, the liquid formulation advantageously may be supplied
in a conventional bottle with a sprayer. The sprayer can be a
trigger sprayer. As an option to a trigger sprayer, an aerosol can
also be used to deliver the liquid formulation on to surfaces.
Additional application means include, but are not limited to,
fogging, rolling, brushing, mopping, and using a wipe by a variety
of application devices. It is within the scope of the present
invention that wipe products can also be made comprising or
pre-treated with the disinfectant formulation(s) of the present
invention, for example, for off-the-shelf sale or use.
[0125] To disinfect a contaminated surface, spray the liquid
formulation until the area is completely covered. The wet
formulation subsequently may be wiped dry with a dry cloth or paper
towel.
[0126] The invention also relates to an article treated with a
disinfectant formulation in accordance with aspects of the
invention.
Examples
[0127] The following examples illustrate liquid formulations made
in accordance with aspects of the present invention. The testing
results on these formulations demonstrate the desired residual
sanitizing or disinfecting performance once being applied onto
surfaces and dried. Cleaning performance is also tested on those
formulations that not only provide residual disinfecting benefit
but also cleaning features.
[0128] Formulations were tested for residual efficacy using the EPA
01-1A protocol. Briefly, bacteria were added to a glass slide and
allowed to dry on the surface. The formulation was then sprayed
onto the surface and dried to form a transparent film. Once a film
had formed, the glass slide was exposed to alternating wet and dry
cycles using the Gardner wear tester as described in the protocol.
In between each cycle the slide was re-inoculated with bacteria.
After the appropriate number of wear and re-inoculations (48 passes
and 11 re-inoculations for healthcare formulation and 24 passes 5
re-inoculation for homecare formulation) the slide was exposed to
bacteria for the indicated time frame (i.e. 5 minutes) followed by
recovery in an appropriate neutralizing solution.
[0129] In addition to residual efficacy, initial efficacy of the
composition of the present invention was also tested according to
ASTM E 1153.
[0130] A modified ASTM D4488 was used to evaluate the hard surface
cleaning performance for the home care composition of the present
invention. A soil of the following composition was used for the
evaluation.
TABLE-US-00001 TABLE 1 Weight percentage of each Components
component (%) Pure vegetable oil 75 TM-122 AATCC carpet soil 25
*TM-122 AATCC carpet soil was obtained from Textile Innovators
[0131] In the process of making a soiled ceramic tile for the
cleaning test, around 2 grams of the liquid soil was placed on an
aluminum foil. A roller was used to roll and spread out the soil on
the foil and let the roller pick up the soil as much as possible.
The soil on the roller was transferred to the glazed surface of a
ceramic tile evenly by rolling the soiled roll on the ceramic
surface. The soiled ceramic tile was then baked in oven set at 180
C for 45 minutes. The baked tile was conditioned at room
temperature for 24 hours before being used for the cleaning
test.
[0132] A Gardner wear tester was used in the cleaning test.
Scouring pads of around 1 cm width were attached to the abrasion
boat for the wearing. Around 4 grams of test formulation was placed
in a weighing boat. The attached scouring pad was dipped into the
weighing boat to pick up the testing formulation.
[0133] The cleaning process started immediately after the pad is
wetted with the cleaning formulation. Seven wearing cycles (back
and forth) were used in the test.
Residual Disinfectant Examples for Healthcare
[0134] The following formulation in the example uses alcohol as the
major carrier in order to provide fast drying property to the
liquid formulations.
TABLE-US-00002 TABLE 2 HE1 HE2 HE3 Components (wt %) (wt %) (wt %)
Water balance balance balance Ethanol 70 70 0 2-Propanol 0 0 70
Polyethyloxazoline 2 2 2 Quaternary 0.8 1.2 1.2 ammonium compound
Wetting 0.1 0.1 0.1 agent/Surfactant
[0135] The residual efficacy testing was conducted using EP01-1A
protocol and the results are listed in the following Table.
TABLE-US-00003 TABLE 3 EP01-1A (average log reduction Formulation
bacterial) HE1 3.53 HE2 5.50 HE3 4.50
[0136] These formulations show excellent residual efficacy result
based on EP01-1A test.
[0137] The ASTM E 1153 test protocol was also followed to assess
the initial biocidal property of HE2. Test results are presented in
the following table.
TABLE-US-00004 TABLE 4 Method Time Complete kill (<10 Initial
Efficacy 3 log reduction CFU/PFU) Bacterial Klebsiella 30 seconds 1
minute ASTM E 1153 pneumoniae Pseudomonas 30 seconds 30 seconds
ASTM E 1153 aerugniosa Staphylococcus 30 seconds 30 seconds ASTM E
1153 aureus MRSA 30 seconds 30 seconds ASTM E 1153 VRE 30 seconds
30 seconds ASTM E 1153 Enterobacter 30 seconds 30 seconds ASTM E
1153 aerogenes Enterococcus 30 seconds 1 minute ASTM E 1153
faecalis Fungal Aspergillus niger 1 minute 5 minutes ASTM E 1153
Tricophyton 1 minute 5 minutes ASTM E 1153 mentagrophytes Viral
H1N1 (envelope) 30 seconds 30 seconds ASTM E 1053 MS2 (Non- 30
seconds 5 minutes ASTM E 1053 enveloped) Time frame of Residual
Efficacy exposure Log reduction Method Pseudomonas 5 minutes >3
EPA 01-1A aerugniosa Enterobacter 5 minutes >3 EPA 01-1A
aerogenes Staphylococcus 5 minutes >3 EPA 01-1A aureus
[0138] These data clearly demonstrate that sample surfaces treated
with the exemplary liquid formulation disclosed herein possess a
demonstrable biocidal activity at the indicated time frame.
Residual Disinfectant Cleaner Examples for Homecare
[0139] These compositions are formulated using water as the
carrier. They are intended for homecare use where VOC regulations
prohibit most use of high levels of organic solvents such as
alcohols.
TABLE-US-00005 TABLE 5 H1 H2 H3 H4 H5 Components (wt %) (wt %) (wt
%) (wt %) (wt %) Water balance balance balance balance balance EDTA
tetra sodium 0 0 0 0 0.4 Polyethyloxazoline 1 1 1 0.5 0.5
Ethoxylated alcohol 0.33 0 0 0 0 #1 Ethoxylated alcohol 0 0 0.2 0.2
0.2 #2 Quaternary 0.4 0.4 0.4 0.4 0.4 ammonium compound
Ethanolamine 0.2 0.2 0.2 0.2 0.2 Wetting Agent 0.1 0.1 0.1 0.1
0.1
[0140] The residual efficacy of these formulations were assessed
using EP01-1A protocol and the results are listed in the following
Table.
TABLE-US-00006 TABLE 6 EP01-1A (average log reduction Formulation
bacterial) H1 3.53 H2 5.50 H3 5.50 H4 4.90 H5 3.80
[0141] Enterobacter aerogenes was the bacterial for H1 testing and
Staphylococcus aureus was the bacteria used in the testing for the
rest of the formulations.
[0142] The testing results demonstrate that the H1 to H5 all
provide residual efficacy to the treated surfaces. The cleaning
performance was also evaluated using the modified ASTM D4488 test
method.
[0143] The testing results also clearly visually showed the
formulation of present invention not only provided residual
efficacy against bacterial but also good cleaning performance on
soiled surfaces.
[0144] Additional formulations set forth in the Tables below were
tested for home care and home cleaning applications. To solubilize
the fragrance, a pre-mix is prepared containing the fragrance,
quaternary ammonium compound, surfactant and glycol ether if
present.
TABLE-US-00007 TABLE 7 Light Duty Protectant Formulations P1 P2 P3
P4 P5 P6 P7 P8 P9 P10 P11 P12 P13 P14 P15 (wt (wt (wt (wt (wt (wt
(wt (wt (wt (wt (wt (wt (wt (wt (wt Component %) %) %) %) %) %) %)
%) %) %) %) %) %) %) %) Polyethyl- 1.00 1.00 1.00 1.00 1.00 1.00
1.00 1.00 1.00 1.00 0.50 1.00 0.50 1.00 0.50 oxazoline Quaternary
0.40 0.40 0.40 0.40 0.40 0.40 0.40 0.40 0.40 0.40 0.40 0.20 0.20
0.10 0.10 ammonium compound Fragrance 0.05 0.05 0.05 0.05 0.05 0.05
0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 Wetting 0.30 0.10 0.10
0.10 0.10 0.10 0.10 agent Amine 0.30 0.30 0.30 0.30 0.30 Oxide
Ethoxylated 0.30 Cationic surfactant Dicoco quat 0.30 Ethoxylated
0.30 alcohol Triethanol- 0.50 0.50 0.50 0.50 0.50 0.50 0.50 amine
NaEDTA 0.10 Sodium 0.10 metasilicate pentahydrate Sodium 0.10
Carbonate Water* B B B B B B B B B B B B B B B P16 P17 P18 P19 P20
P21 P22 P23 P24 P25 P26 P27 P28 P29 (wt (wt (wt (wt (wt (wt (wt (wt
(wt (wt (wt (wt (wt (wt Component %) %) %) %) %) %) %) %) %) %) %)
%) %) %) Polyethyl- 1.00 0.50 1.00 0.50 1.00 0.50 1.00 0.50 1.00
1.00 1.00 0.50 0.50 0.50 oxazoline Quaternary 0.20 0.20 0.10 0.10
0.20 0.20 0.10 0.10 0.20 0.20 0.20 0.20 0.20 0.20 ammonium compound
Fragrance 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05 0.05
0.05 0.05 0.05 Wetting agent Amine 0.30 0.30 0.30 0.30 Oxide
Ethoxylated Cationic surfactant Dicoco quat Ethoxylated 0.20 0.20
0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 alcohol Triethanol- 0.50
0.50 0.50 0.50 0.50 0.50 0.50 0.50 amine NaEDTA 0.10 0.10 Sodium
0.10 0.10 metasilicate pentahydrate Sodium 0.10 0.10 Carbonate
Water* B B B B B B B B B B B B B B *B means balance water
TABLE-US-00008 TABLE 8 All Purpose Cleaner Formulations A1 A2 A3 A4
A5 A6 A7 A8 A9 A10 A11 A12 A13 A14 A15 A16 (wt (wt (wt (wt (wt (wt
(wt (wt (wt (wt %) (wt %) (wt %) (wt %) (wt %) (wt %) (wt %)
Component %) %) %) %) %) %) %) %) %) Polyethyl- 1.00 1.00 1.00 1.00
1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.20 1.00 1.20 1.00 1.0
oxazoline Quaternary 0.40 0.40 0.40 0.40 0.40 0.40 0.40 0.40 0.40
0.40 0.50 0.50 0.40 0.80 0.40 0.80 ammonium compound Fragrance 0.10
0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10
0.10 0.10 Amine 0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.60 0.45 0.45
0.60 0.60 0.60 0.45 0.60 Oxide Ethoxylated 0.50 Alcohol 1
Ethoxylated Alcohol 2 Alkyl- polyglucoside Tri- 1.0 ethanolamine
Glycol Ether 1 5.00 Glycol Ether 2 NaEDTA 0.40 Sodium 0.10 0.25
0.25 0.25 0.10 0.10 0.10 0.10 0.10 metasilicate pentahydrate Sodium
0.10 Carbonate STPP 0.10 TKPP 0.10 Water* B B B B B B B B B B B B B
B B B A17 A18 A19 A20 A21 A22 A23 A24 A25 A26 A27 A28 A29 A30 A31
A32 (wt (wt (wt (wt (wt (wt (wt (wt (wt (wt %) (wt %) (wt %) (wt %)
(wt %) (wt %) (wt %) Component %) %) %) %) %) %) %) %) %)
Polyethyl- 0.80 0.80 1.0 1.00 1.20 1.00 1.00 1.00 1.00 1.00 1.00
1.00 1.00 1.00 1.00 1.00 oxazoline Quaternary 0.50 0.50 0.50 0.50
0.50 0.50 0.50 0.50 0.50 0.50 0.50 0.50 0.50 0.50 0.50 0.50
ammonium compound Fragrance 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10
0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 Amine Oxide 0.60 0.60 1.50
1.20 0.60 0.60 Ethoxylated 0.10 0.20 0.60 0.60 0.80 Alcohol 1
Ethoxylated 0.10 0.20 0.20 0.80 Alcohol 2 Alkyl- 0.60 0.50 0.50
0.40 0.40 0.40 polyglucoside Tri- 0.50 0.50 0.50 0.50 0.50 0.50
0.50 ethanolamine Glycol Ether 1 5.00 2.40 2.40 Glycol Ether 2 2.40
2.40 2.40 NaEDTA Sodium 0.10 0.05 0.05 0.05 0.05 0.05 metasilicate
pentahydrate Sodium Carbonate STPP TKPP Water* B B B B B B B B B B
B B B B B B
TABLE-US-00009 TABLE 9 Bathroom Cleaner Formulations B1 B2 B3 B4 B5
B6 B7 B8 B9 B10 B11 B12 Component (wt %) (wt %) (wt %) (wt %) (wt
%) (wt %) (wt %) (wt %) (wt %) (wt %) (wt %) (wt %) Polyethyl- 1.00
1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 oxazoline
Quaternary 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20
0.20 ammonium compound Fragrance 0.10 0.10 0.10 0.10 0.10 0.10 0.10
0.10 0.10 0.10 0.10 0.10 Amine 0.84 0.42 0.84 0.42 0.84 0.42 0.84
0.42 Oxide Ethoxylated 0.84 0.84 0.84 0.84 alcohol 1 Ethoxylated
0.50 0.50 0.50 0.50 alcohol 2 Glycol Ether 4.00 4.00 4.00 4.00 4.00
4.00 NaEDTA 2.90 2.90 2.90 2.90 2.90 2.90 Citric Acid 2.50 2.50
2.50 2.50 2.50 2.50 Sulfamic Acid Water* B B B B B B B B B B B B
B13 B14 B15 B16 B17 B18 B19 B20 B21 B22 B23 B24 Component (wt %)
(wt %) (wt %) (wt %) (wt %) (wt %) (wt %) (wt %) (wt %) (wt %) (wt
%) (wt %) Polyethyl- 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
1.00 1.00 1.00 oxazoline Quaternary 0.20 0.20 0.20 0.80 0.80 0.80
0.80 0.80 0.80 0.80 0.80 0.80 ammonium compound Fragrance 0.10 0.10
0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 0.10 Amine 0.84 0.42
0.80 0.40 0.80 0.40 0.80 0.40 Oxide Ethoxylated 0.84 0.80 0.80 0.80
alcohol 1 Ethoxylated 0.50 0.50 0.50 0.50 alcohol 2 Glycol Ether
4.00 4.00 4.00 4.0 4.0 4.0 4.0 NaEDTA Citric Acid 2.50 2.50 2.50
2.50 2.50 2.50 Sulfamic Acid 2.50 2.50 2.50 2.50 2.50 2.50 Water* B
B B B B B B B B B B B
[0145] A concentrate of a water based formulation is prepared by
removing a portion of the water from the formulation, concentrating
the remaining raw materials. The resulting concentrate can then be
diluted back to use strength prior to use. The 5 times and 10 times
concentrates are typically used in the janitorial and sanitization
supply industries with customers in the hospitality area.
Concentrates are desirable in these industries as it reduces
shipping costs and conserves storage space. Table 10 illustrates
example concentrate formulations in an embodiment of the
invention.
TABLE-US-00010 TABLE 10 Concentrate Formulations All All Pro- Pro-
Purpose Purpose Bathroom Bathroom tectant tectant Cleaner Cleaner
Cleaner Cleaner Component 5X 10X 5X 10X 5X 10X Polyethyl- 5.0 10
5.0 10 5.0 10 oxazoline Quaternary 1.0 2.0 2.5 5.0 1.6 3.2 ammonium
compound Fragrance 0.25 0.50 0.5 1.0 0.75 1.5 Surfactant 0.50 1.0
4.0 8.0 3.0 6.0 Glycol Ether 12.5 25 TEA 2.5 5.0 Citric Acid 12.5
25 Water* B B B B B B
Comparative Example
[0146] Multiple polymeric compounds were tested for the capability
to provide persistent bioburden reduction utilizing the EPA 01-1A
protocol against Enterobacter aerogenes. 50 microL of each
formulation was allowed to dry on glass carriers before being
subjected to the test. Each test was conducted in the presence of
5% FBS. As noted in Table 11, the combination of polyoxazoline and
quaternary ammonium provided a synergistic residual sanitizing
benefit.
TABLE-US-00011 TABLE 11 Formula 1 Formula 2 Formula 3 Formula 4
Formula 5 Active Quaternary Quaternary Quaternary Quaternary
Quaternary Ingredient Ammonium Ammonium Ammonium Ammonium Ammonium
blend blend blend blend blend Polymer 3 Glycidoxypropyl-
Trimethoxysilyl- acrylic polyamide polyoxazoline trimethoxysilane
propyl emulsion resin (Polyethyleneimine) SSP-060 Aesthetics Hazy
film Tacky film when dry Clear, non clear, non Clear, non tacky
film tacky film tacky film Associated NT* NT* 0.5 log 1.8 log 5 log
reduction Log reduction reduction Reduction *indicates not tested
due to poor aesthetics
[0147] It will therefore be readily understood by those persons
skilled in the art that the present composition and methods are
susceptible of broad utility and application. Many embodiments and
adaptations other than those herein described, as well as many
variations, modifications and equivalent arrangements, will be
apparent from or reasonably suggested to one of ordinary skill by
the present disclosure and the foregoing description thereof,
without departing from the substance or scope thereof.
[0148] Accordingly, while the present composition and methods have
been described herein in detail in relation to its preferred
embodiment, it is to be understood that this disclosure is only
illustrative and exemplary and is made merely for purposes of
providing a full and enabling disclosure.
[0149] The foregoing disclosure is not intended or to be construed
to limit or otherwise to exclude any such other embodiments,
adaptations, variations, modifications and equivalent
arrangements.
* * * * *